CN120187722A - 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式 - Google Patents

一种吡唑并杂芳基类衍生物的可药用盐的结晶形式 Download PDF

Info

Publication number
CN120187722A
CN120187722A CN202380078800.2A CN202380078800A CN120187722A CN 120187722 A CN120187722 A CN 120187722A CN 202380078800 A CN202380078800 A CN 202380078800A CN 120187722 A CN120187722 A CN 120187722A
Authority
CN
China
Prior art keywords
cancer
formula
mesylate
compound represented
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380078800.2A
Other languages
English (en)
Chinese (zh)
Inventor
姚佳琪
杨俊然
杜振兴
王捷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN120187722A publication Critical patent/CN120187722A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380078800.2A 2022-11-21 2023-11-21 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式 Pending CN120187722A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022114519333 2022-11-21
CN202211451933 2022-11-21
PCT/CN2023/132860 WO2024109727A1 (fr) 2022-11-21 2023-11-21 Forme cristalline d'un sel pharmaceutiquement acceptable d'un dérivé de pyrazolo hétéroaryle

Publications (1)

Publication Number Publication Date
CN120187722A true CN120187722A (zh) 2025-06-20

Family

ID=91195288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380078800.2A Pending CN120187722A (zh) 2022-11-21 2023-11-21 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式

Country Status (2)

Country Link
CN (1) CN120187722A (fr)
WO (1) WO2024109727A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423760A (zh) * 2019-11-21 2022-04-29 江苏恒瑞医药股份有限公司 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN114790205A (zh) * 2021-01-26 2022-07-26 江苏恒瑞医药股份有限公司 氘代吡唑并吡啶类化合物、其制备方法及其在医药上的应用
CN115368355A (zh) * 2021-05-21 2022-11-22 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的结晶形式
CN117355524A (zh) * 2021-05-21 2024-01-05 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐及其结晶形式

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423760A (zh) * 2019-11-21 2022-04-29 江苏恒瑞医药股份有限公司 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN114790205A (zh) * 2021-01-26 2022-07-26 江苏恒瑞医药股份有限公司 氘代吡唑并吡啶类化合物、其制备方法及其在医药上的应用
CN115368355A (zh) * 2021-05-21 2022-11-22 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的结晶形式
CN117355524A (zh) * 2021-05-21 2024-01-05 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐及其结晶形式

Also Published As

Publication number Publication date
WO2024109727A1 (fr) 2024-05-30

Similar Documents

Publication Publication Date Title
EP4640689A1 (fr) Forme cristalline d'un inhibiteur de kras g12d et son procédé de préparation
CN108779126B (zh) 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3，2-d]嘧啶-4(3h)-酮半水合物的结晶形式
TW201109334A (en) PLK inhibitor salts
CN105431147A (zh) 2-羟基-6-((2-(1-异丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛的游离碱的结晶多晶型物
US11332467B2 (en) Solid state forms of palbociclib dimesylate
WO2018197653A9 (fr) Polymorphes, formes solides de (s)-2-((2-((s)-4-(difluorométhyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazépin-9-yl)amino)propanamide, et procédés de production
CN110536888B (zh) 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
JP2022523035A (ja) １，２，３－トリアゾロ［１，５－ａ］ピラジン誘導体の結晶形および結晶形の調製方法
IL323224A (en) Crystalline form
EP4342897A1 (fr) Sel pharmaceutiquement acceptable de dérivé de pyrazolohétéroaryle et forme cristalline de celui-ci
BR112020005964A2 (pt) intermediário de linagliptina cristalina e processo para preparação de linagliptina
WO2024109727A1 (fr) Forme cristalline d'un sel pharmaceutiquement acceptable d'un dérivé de pyrazolo hétéroaryle
WO2023143576A1 (fr) Forme cristalline ou forme amorphe de composé macrocyclique ou de sel ou de solvate de celui-ci
CN116375711A (zh) 一种shp2抑制剂的可药用盐、晶型及其制备方法
CN115368355A (zh) 一种吡唑并杂芳基类衍生物的结晶形式
EP3461823A1 (fr) Forme cristalline de chlorhydrate de plx3397, procédé pour sa préparation et utilisation correspondante
EP3819296B1 (fr) Procédé de production de dérivés de diarylpyridine
WO2016157136A1 (fr) Formes cristallines de l'idélalisib
EP4464712A1 (fr) Forme cristalline d'un composé promédicament antagoniste de la neurokinine-1
BR112020006051A2 (pt) formas cristalinas de lenalidomida
JP2024535857A (ja) 縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法
EP4709478A1 (fr) Formes cristallines de 2-[3-(2,2,6,6-tétraméthylpipéridin-4-yl)-3h-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2h-1,2,3-triazol-2-yl)phénol
CN117924287A (zh) 一种杂环取代的稠合γ-咔啉类衍生物的盐、晶型及其制备方法和应用
TW202602874A (zh) Akt1抑制劑及其鹽之固態形式
JP2026502614A (ja) Ｃｄｋ阻害剤およびその薬学的に許容される塩の結晶形ならびにそれらの使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40128332

Country of ref document: HK